Waldron Private Wealth LLC Boosts Stake in Johnson & Johnson (NYSE:JNJ)

Waldron Private Wealth LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,865 shares of the company’s stock after purchasing an additional 937 shares during the period. Waldron Private Wealth LLC’s holdings in Johnson & Johnson were worth $3,463,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of JNJ. Evolution Wealth Advisors LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $40,000. Thor Advisors LLC purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $69,000. Personal Wealth Partners purchased a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $73,000. Quattro Financial Advisors LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $92,000. Finally, Financial Gravity Wealth Inc. raised its stake in shares of Johnson & Johnson by 36.9% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 809 shares of the company’s stock valued at $113,000 after acquiring an additional 218 shares during the period. 67.23% of the stock is currently owned by institutional investors.

Shares of JNJ stock traded down $2.43 during trading on Friday, reaching $128.84. The company’s stock had a trading volume of 8,673,103 shares, compared to its average volume of 6,802,085. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. The company has a market capitalization of $344.68 billion, a price-to-earnings ratio of 15.75, a P/E/G ratio of 2.21 and a beta of 0.69. The stock’s 50-day moving average price is $132.92 and its 200 day moving average price is $136.56. Johnson & Johnson has a 1-year low of $121.00 and a 1-year high of $148.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.42 by $0.16. The firm had revenue of $20.56 billion during the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The business’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.10 earnings per share. On average, sell-side analysts anticipate that Johnson & Johnson will post 8.6 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 2.95%. The ex-dividend date of this dividend is Monday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.

In other news, Director Marillyn A. Hewson purchased 3,000 shares of the stock in a transaction on Tuesday, June 11th. The stock was bought at an average price of $139.68 per share, for a total transaction of $419,040.00. Following the acquisition, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $419,040. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.23% of the company’s stock.

A number of equities research analysts have recently issued reports on JNJ shares. Goldman Sachs Group started coverage on shares of Johnson & Johnson in a research note on Tuesday, May 28th. They issued a “buy” rating on the stock. Credit Suisse Group set a $156.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Thursday, July 18th. Raymond James reduced their price target on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 17th. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Finally, Barclays started coverage on shares of Johnson & Johnson in a research note on Friday, June 21st. They issued a “hold” rating and a $140.00 price target on the stock. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Johnson & Johnson presently has a consensus rating of “Buy” and a consensus target price of $148.56.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: What are popular green investing opportunities?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.